Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK)

doi:10.1182/bloodadvances.2020002846

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	4267-4277
Number of pages	11
Journal	Blood advances
Volume	4
Issue number	18
DOIs	https://doi.org/10.1182/bloodadvances.2020002846
Publication status	Published - 22 Sep 2020

Keywords

ACUTE MYELOID-LEUKEMIA
MINIMAL RESIDUAL DISEASE
HYPOMETHYLATING AGENT THERAPY
CONVENTIONAL CARE REGIMENS
MYELODYSPLASTIC SYNDROME
AZACITIDINE THERAPY
TREATMENT RESPONSE
CLINICAL-RESPONSE
SURVIVAL
TRIAL

Access to Document

10.1182/bloodadvances.2020002846

Cite this

@article{ab2d8f98eeeb42e3a120a30305be17c3,

title = "Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS",

keywords = "ACUTE MYELOID-LEUKEMIA, MINIMAL RESIDUAL DISEASE, HYPOMETHYLATING AGENT THERAPY, CONVENTIONAL CARE REGIMENS, MYELODYSPLASTIC SYNDROME, AZACITIDINE THERAPY, TREATMENT RESPONSE, CLINICAL-RESPONSE, SURVIVAL, TRIAL",

author = "Gerwin Huls and Chitu, {Dana A.} and Thomas Pabst and Klein, {Saskia K.} and Georg Stussi and Laimonas Griskevicius and Valk, {Peter J. M.} and Jacqueline Cloos and {van de Loosdrecht}, {Arjan A.} and Dimitri Breems and {van Lammeren-Venema}, Danielle and {van Zeventer}, Isabelle and Rinske Boersma and Mojca Jongen-Lavrencic and Martin Fehr and Mels Hoogendoorn and Manz, {Markus G.} and Maaike Sohne and Kooy, {Rien van Marwijk} and Dries Deeren and {van der Poel}, {Marjolein W. M.} and Legdeur, {Marie Cecile} and Lidwine Tick and Yves Chalandon and Emanuele Ammatuna and Sabine Blum and Bob Lowenberg and Ossenkoppele, {Gert J.} and {Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)} and {Swiss Group for Clinical Cancer Research (SAKK)}",

year = "2020",

month = sep,

day = "22",

doi = "10.1182/bloodadvances.2020002846",

language = "English",

volume = "4",

pages = "4267--4277",

journal = "Blood advances",

issn = "2473-9529",

publisher = "The American Society of Hematology",

number = "18",

}

TY - JOUR

T1 - Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

AU - Huls, Gerwin

AU - Chitu, Dana A.

AU - Pabst, Thomas

AU - Klein, Saskia K.

AU - Stussi, Georg

AU - Griskevicius, Laimonas

AU - Valk, Peter J. M.

AU - Cloos, Jacqueline

AU - van de Loosdrecht, Arjan A.

AU - Breems, Dimitri

AU - van Lammeren-Venema, Danielle

AU - van Zeventer, Isabelle

AU - Boersma, Rinske

AU - Jongen-Lavrencic, Mojca

AU - Fehr, Martin

AU - Hoogendoorn, Mels

AU - Manz, Markus G.

AU - Sohne, Maaike

AU - Kooy, Rien van Marwijk

AU - Deeren, Dries

AU - van der Poel, Marjolein W. M.

AU - Legdeur, Marie Cecile

AU - Tick, Lidwine

AU - Chalandon, Yves

AU - Ammatuna, Emanuele

AU - Blum, Sabine

AU - Lowenberg, Bob

AU - Ossenkoppele, Gert J.

AU - Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

AU - Swiss Group for Clinical Cancer Research (SAKK)

PY - 2020/9/22

Y1 - 2020/9/22

KW - ACUTE MYELOID-LEUKEMIA

KW - MINIMAL RESIDUAL DISEASE

KW - HYPOMETHYLATING AGENT THERAPY

KW - CONVENTIONAL CARE REGIMENS

KW - MYELODYSPLASTIC SYNDROME

KW - AZACITIDINE THERAPY

KW - TREATMENT RESPONSE

KW - CLINICAL-RESPONSE

KW - SURVIVAL

KW - TRIAL

U2 - 10.1182/bloodadvances.2020002846

DO - 10.1182/bloodadvances.2020002846

M3 - Article

VL - 4

SP - 4267

EP - 4277

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 18

ER -